A subset of GBM harbors oncogenic fusions that join the members of FGFR3 and FGFR1 tyrosine kinases to the transforming acidic coiled-coil (TACC) proteins TACC3 and TACC1, respectively, and it is hoped that the inhibition of FGFR could be a valuable therapeutic option for this subgroup of deadly types of brain cancer or other cancers [17]. The gene discussed is FGFR3; the disease is glioblastoma.